BEAM at a glance
Beam Therapeutics Inc. (BEAM, SEC CIK 1745999) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Beam Therapeutics Inc. (BEAM) reported revenue of $139.7 million (up 120.0% from FY2024) and a net loss of $80.0 million. Diluted EPS was -$0.81.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Beam Therapeutics Inc. (BEAM) shares worth $2.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cavanagh Bethany J on October 1, 2026 of 187 shares at $24.41 per share.
- In the last 90 days, BEAM insiders reported 0 open-market purchases ($0) and 2 open-market sales ($434K) on Form 4, a net sale of $434K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $139.7M
- +120.0% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$434K
- 13F holders
- 32 funds
- $2.1B · +3 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Fully integrated precision genetic medicines platform based on proprietary base editing gene editing technology without DNA double-strand breaks
- New products/segments: Announced BEAM-304 for phenylketonuria (PKU) and advancing in vivo LNP liver-targeted base editors BEAM-302 (AATD) and BEAM-301 (GSDIa)
- Strategic shift: Prioritizing in vivo base editing delivery modalities for hematopoietic stem cells to expand sickle cell disease treatment beyond ex vivo autologous stem cell therapies
- Quantitative metric: Completed dosing manufacture for risto-cel (BEAM-101) in 31 patients with mean editing efficiency 67.4% at 6 months and 72.8% at 12 months
- Noteworthy fact: FDA alignment on accelerated approval pathway for BEAM-302 based on 12-month biomarker data, with planned enrollment of ~50 additional patients in pivotal expansion
Risk Factors
- Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents
- Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership
- Company-wide annual employee training on data protection and incident response covering phishing and social engineering
- Use of technology-based tools combined with employee programs to mitigate cybersecurity risks
Management Discussion & Analysis
- Revenue $139.7M in 2025 vs $63.5M in 2024 and $377.7M in 2023, primarily from license and collaboration agreements
- Net loss $80.0M in 2025 vs $376.7M loss in 2024 and $132.5M loss in 2023, accumulated deficit $1.6B at 2025 year-end
- Hematology segment (ristocel) showing clinical progress with high editing efficiency (67.4% at Month 6, 72.8% at Month 12) and upcoming BLA submission planned for year-end 2026
- $100M initial draw on $500M senior secured Credit Facility entered Feb 2026, interest rate SOFR +6.50%, no product sales revenue yet, capital raises expected for ongoing R&D
- Forward outlook: dose expansions and clinical updates in 2026 for hematology and genetic disease programs; key risks include capital needs, regulatory approvals, and execution of clinical development
AI summary of the BEAM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes identified; filing text is truncated before the formal Risk Factors section
- Regulatory risk: FDA approval for BEAM-302 depends on 12-month AAT biomarkers under an accelerated pathway
- Clinical risk: one risto-cel patient died four months post-infusion from respiratory failure likely related to busulfan conditioning
- Operational risk: pivotal BEAM-302 expansion requires approximately 50 additional patients
- Financial risk: $217.0 million six-month net loss and $1.9 billion accumulated deficit as of June 30, 2026
AI summary of the BEAM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial details and management commentary
Item EX-99.1: Item EX-99.1
- BEAM-302 entered global pivotal dosing, advancing AATD toward potential accelerated approval and creating a major 2026 clinical catalyst
- Risto-cel dosing completed in adult and adolescent BEACON patients, with updated data and potential BLA submission by year-end 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders re-elected John Evans, John Maraganore, and Christi Shaw as Class III directors through the 2029 annual meeting
- Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial details
AI summaries of BEAM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BEAM
Don't miss the next BEAM filing
- Alerts as it files. A push when BEAM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BEAM, by share count.
- Ask anything. An AI agent that reads every BEAM filing and answers with sources.
BEAM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cavanagh Bethany J | Sell | Oct 1, 2026 | 187 | $24.41 |
| Ciaramella Giuseppe | G | Sep 24, 2026 | 123,407 | - |
| Simon Amy | Sell | Jul 27, 2026 | 16,667 | $25.74 |
| Evans John M. | M | Jun 30, 2026 | 25,000 | $1.03 |
| Simon Amy | Sell | Jun 30, 2026 | 373 | $34.73 |
| Evans John M. | Sell | Jun 30, 2026 | 23,100 | $34.26 |
| Evans John M. | M | Jun 30, 2026 | 25,000 | - |
| Evans John M. | Sell | Jun 30, 2026 | 1,900 | $34.84 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $377.7M | $63.5M | $139.7M |
| Operating Income | - | -$415.6M | -$383.7M |
| Net Income | -$132.5M | -$376.7M | -$80.0M |
| Op. Margin | - | -654.3% | -274.6% |
| Net Margin | -35.1% | -593.1% | -57.2% |
| Balance Sheet | |||
| Total Assets | - | $1.1B | $1.5B |
| Equity | - | $733.5M | $1.2B |
| ROE | - | -51.4% | -6.5% |
| Per Share | |||
| EPS | $-1.72 | $-4.58 | $-0.81 |
| Cash Flow | |||
| Operating CF | - | -$347.2M | -$345.1M |
| CapEx | $33.7M | $8.9M | $14.9M |
Source: XBRL data in Beam Therapeutics Inc. (BEAM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BEAM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $2.11B |
| Q1 2026 | 29 | $1.42B |
| Q4 2025 | 26 | $1.62B |
| Q3 2025 | 28 | $1.33B |
| Q2 2025 | 28 | $964.7M |
| Q1 2025 | 22 | $744.6M |
| Q4 2024 | 18 | $659.9M |
| Q3 2024 | 16 | $366.3M |
- Morgan Stanley+1.30M (+201%)
- T. Rowe Price Group+702.0K (+26%)
- BlackRock+510.0K (+6%)
- Vanguard Portfolio Management LLC+350.5K (+8%)
- Goldman Sachs Group+304.3K (+30%)
- ARK Investment Management−1.90M (-16%)
- Renaissance Technologies LLC−68.6K (-13%)
- JPMorgan Chase & Co−36.6K (-7%)
- Invesco Ltd−25.8K (-12%)
- D.E. Shaw & Co+130.6K
- Ameriprise Financial+8.9K
- Marex Group plc+7.0K
- Principal Financial Group+7.0K
- Citadel Advisors LLC−529.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BEAM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
BEAM SEC filings: frequently asked questions
Are BEAM insiders buying or selling?
In the last 90 days, Beam Therapeutics Inc. (BEAM) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $433,602 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BEAM stock?
As of June 30, 2026, the largest Beam Therapeutics Inc. (BEAM) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($432.7 million), ARK Investment Management ($351.3 million), BlackRock ($308.8 million), State Street Corp ($200.0 million), Vanguard Portfolio Management LLC ($168.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BEAM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Beam Therapeutics Inc. (BEAM) reported revenue of $139.7 million (up 120.0% from FY2024) and a net loss of $80.0 million. Diluted EPS was -$0.81. The figures come from the XBRL data in the 10-K.
What are the main risks in BEAM's latest 10-K?
In the 10-K filed February 24, 2026, Beam Therapeutics Inc. (BEAM) flagged: Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents. Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership. (AI summary of the Risk Factors section.)
What did BEAM report in its latest 8-K?
Beam Therapeutics Inc. (BEAM) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest BEAM SEC filings?
Beam Therapeutics Inc. (BEAM) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on October 2, 2026.
What is BEAM's SEC CIK number?
Beam Therapeutics Inc. (BEAM)'s SEC Central Index Key (CIK) is 1745999. EDGAR lists every BEAM filing under that number.
Ask anything about BEAM
The research agent reads BEAM's filings, financials, insider trades and 13F holders, then answers with sources.